Type 2 Diabetes Mellitus Clinical Trial
Official title:
Tai Chi Quan Improving Blood Glucose, Blood Lipid, and Quality of Life in Patients With Type 2 Diabetes
In this study, the hypothesis that the 12-week Tai Chi Quan training would have better control of blood sugar, biochemistry profile, and also better quality of life and activity of autonomic nerve system (ANS). The subjects were randomize assigned to either Tai Chi group or control group. The outcome measures before and after 12-week intervention include basic demographic characteristics, HbA1c, fasting blood glucose(FBG), triglycerides (TG), high and low density lipoprotein (HDL, LDL), creatinine(Cr), eGFR, GPT, ACR, quality of life, and activity of automatic nerve system.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2018 |
Est. primary completion date | September 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: - 40~80 years old - Diagnosed type 2 diabetes mellitus, and without changing dietary pattern and medical treatment for blood glucose or blood lipid. - Consciousness clear and is voluntary to attend the project and with the agreement. - The functional movement ability is independent Exclusion Criteria: - Pregnant or plan to be pregnant in six months, and breast feeding. - Severe complication in six months such as myocardial infarction, stroke, severe traumatic injury, major surgery. Other diseases evaluated by the doctor that are not suitable for the project. - Evaluated that the compliance for the intervention is not appropriate. - The blood glucose > 300mg/dl and unable to do vigorous exercise. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Linsen Chinese Medicine and Kunming Branch, Taipei City Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Taipei City Hospital | National Yang Ming University |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hemoglobin | HbA1c | change from Baseline to 12 weeks | |
Secondary | fasting blood glucose | blood sample after 8-hour fasting | change from Baseline to 12 weeks | |
Secondary | triglycerides | blood sample after 8-hour fasting | change from Baseline to 12 weeks | |
Secondary | high and low density lipoprotein | blood sample after 8-hour fasting | change from Baseline to 12 weeks | |
Secondary | creatinine | blood sample after 8-hour fasting | change from Baseline to 12 weeks | |
Secondary | estimated Glomerular Filtration Rate (eGFR) | blood sample after 8-hour fasting | change from Baseline to 12 weeks | |
Secondary | Glutamic-Pyruvic Transaminase (GPT) | blood sample after 8-hour fasting | change from Baseline to 12 weeks | |
Secondary | urine albumin/creatinine ratio (ACR) | from urine sample | change from Baseline to 12 weeks | |
Secondary | quality of life | WHOQOL-BREF Taiwan | change from Baseline to 12 weeks | |
Secondary | heart rate variability | represent for balance of autonomic nervous system | change from Baseline to 12 weeks | |
Secondary | low frequency (LF) | Low frequency is the frequency domain analysis from heart rate variability, and is represent for sympathetic nervous system | change from Baseline to 12 weeks | |
Secondary | high frequency (HF) | High frequency is the frequency domain analysis from heart rate variability, and is represent for parasympathetic nervous system | change from Baseline to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |